Denali reports FY2024 net loss $422.8M; BLA for MPS II drug planned early 2025

Denali Therapeutics Inc.

2024-FY EPS reported -$2.57

Net loss $114.8M Q4 and $422.8M FY2024, vs $119.5M and $145.2M in prior year.
No collaboration revenue in 2024; FY2023 had $330.5M from Biogen, Sanofi, Takeda.
New ATM equity facility up to $400M; prior ATM terminated; Goldman & Leerink agents.
DNL343 (ALS) missed primary endpoint in HEALEY trial; further analyses expected H2 2025.
2025 cash opex guided +10-15% vs 2024; cash balance $1.19 billion as of Dec 31.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.